A Phase II study of a histamine H3 receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy

L. Fredrik Jarskog, Martin T. Lowy, Richard A. Grove, Richard S.E. Keefe, Joseph P. Horrigan, M. Patricia Ball, Alan Breier, Robert W. Buchanan, Cameron S. Carter, John G. Csernansky, Donald C. Goff, Michael F. Green, Joshua T. Kantrowitz, Matcheri S. Keshavan, Marc Laurelle, Jeffrey A. Lieberman, Stephen R. Marder, Paul Maruff, Robert P. McMahon, Larry J. SeidmanMargaret A. Peykamian

Research output: Contribution to journalArticlepeer-review

41 Scopus citations

Fingerprint

Dive into the research topics of 'A Phase II study of a histamine H3 receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science

Keyphrases